The goal of the Comprehensive Genomics Shared Facility (CGSF) is to provide a spectrum of genomic technologies to support the mission of the University of Alabama-Birmingham Comprehensive Cancer Center (UAB-CCC). The CGSF accomplishes this goal by supporting the high-performance sequencing needs of the center, and providing complementary resources for the established Microarray Shared Facility. Technologies include several platforms for high-performance (next-generation) sequencing, high-throughput gene expression, SNP, DNA copy number, and cytogenetic assays via lllumina, Affymetrix, Agilent and Nlmblegen microarrays and real-time PCR assays. This facility is born from the need for enhanced genomic capabilities that do not fall naturally under the existing CCC facilities that focus on microarray analysis and high-throughput sequencing. Many of the needed technologies were already in place at the HudsonAlpha Institute for Biotechnology (HAIB). Recognizing the efficiency of accessing the technologies available at the compared to building duplicate resources at UAB, the decision was made to create a shared facility that also helped to formalize our deepening collaborative relationships. The diverse technology platforms supported by the facility, in combination with an expert, experienced informatics staff dedicated to UAB-CCC needs and expert scientific leadership provides a comprehensive genomics shared facility to support the mission of the UAB-CCC and research needs of its investigators. Genomic technologies have rapidly become vital to nearly all aspects of biomedical research with particular value to cancer research. Over the last decade, cancer has become recognized as a disease of the genome, and over the last several years several large-scale projects such as The Cancer Genome Atlas (TCGA) project have provided a foundation of knowledge that is just now beginning to be widely leveraged to enhance the analysis of virtually all types of cancer. The genomic and epigenetic changes that have recently been determined to be associated with cellular transformation along with the application of genomic technologies to not only analyze broad cancer types but to also individually tailor treatment regimens for specific patients underscores the importance of the Comprehensive Genomics Shared Facility to the UABCCC.
The underlying defects leading to cancer initiation and progression are increasingly linked to defects in, and damage to, genes. Genomic technologies such as high-performance (next-gen) sequencing have become vital and ubiquitous tools in cancer research. This shared facility provides UAB-CCC members access to these tools with the level of support necessary for the success of both basic and translational research programs. Therefore the Comprehensive Genomics Core meets an integral need of the UAB-CCC.
|Van Arsdale, Anne R; Arend, Rebecca C; Cossio, Maria J et al. (2018) Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Med 7:616-625|
|Kim, Harrison (2018) Modification of population based arterial input function to incorporate individual variation. Magn Reson Imaging 45:66-71|
|Leath 3rd, Charles A; Monk, Bradley J (2018) Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. Gynecol Oncol 150:391-397|
|Park, Misun; Yoon, Young Sup (2018) Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes. Korean Circ J 48:974-988|
|Toboni, Michael D; Smith, Haller J; Bae, Sejong et al. (2018) Predictors of Unplanned Reoperation for Ovarian Cancer Patients From the National Surgical Quality Improvement Program Database. Int J Gynecol Cancer 28:1427-1431|
|Dionne-Odom, J Nicholas; Applebaum, Allison J; Ornstein, Katherine A et al. (2018) Participation and interest in support services among family caregivers of older adults with cancer. Psychooncology 27:969-976|
|Demark-Wahnefried, Wendy; Schmitz, Kathryn H; Alfano, Catherine M et al. (2018) Weight management and physical activity throughout the cancer care continuum. CA Cancer J Clin 68:64-89|
|Bandari, Shyam K; Purushothaman, Anurag; Ramani, Vishnu C et al. (2018) Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol 65:104-118|
|Gowda, Pramod S; Wildman, Benjamin J; Trotter, Timothy N et al. (2018) Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression. Mol Cancer Res 16:1138-1148|
|Dix, Daniel B; McDonald, Andrew M; Gordetsky, Jennifer B et al. (2018) How Would MRI-targeted Prostate Biopsy Alter Radiation Therapy Approaches in Treating Prostate Cancer? Urology 122:139-146|
Showing the most recent 10 out of 747 publications